Access count of this item: 587

Files in This Item:
File Description SizeFormat 
45_799.pdf668.45 kBAdobe PDFView/Open
Title: 進行性胚細胞腫瘍に対する末梢血幹細胞移植(PBSCT)併用超大量化学療法の治療成績
Other Titles: Clinical results of super high-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced germ cell tumor
Authors: 郷司, 和男  KAKEN_name
原, 勲  KAKEN_name
山田, 裕二  KAKEN_name
乃美, 昌司  KAKEN_name
荒川, 創一  KAKEN_name
守殿, 貞夫  KAKEN_name
Author's alias: GOHJI, Kazuo
HARA, Isao
YAMADA, Yuji
NOMI, Masashi
ARAKAWA, Soichi
KAMIDONO, Sadao
Keywords: Germ cell tumor
PBSCT
Super high-dose chemotherapy
Issue Date: Nov-1999
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 45
Issue: 11
Start page: 799
End page: 804
Abstract: 予後不良因子を有する進行性胚細胞腫に対する末梢血幹細胞移植併用超大量化学療法は安全で有用な手段と思われるが,本療法に問題点も残されている
We examined the clinical results of super high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in 14 patients with poor-risk advanced germ cell tumors. The mean number of nadir white blood cells was 205 +/- 126/microliter; the mean period of number of white blood cells fewer than 1,000/microliter was at 8-10 days (mean +/- SD; 9.2 +/- 0.92). The nadir number of blood platelet cells was 1.7 +/- 0.70 x 10(4)/microliter; the mean period of number of platelet cells fewer than 5 x 10(4)/microliter was at 12.6 +/- 2.17 days. Of 10 patients treated with super high-dose chemotherapy with PBSCT as induction therapy, 8 patients (80%) showed that the serum tumor marker returned within the normal range after super high-dose chemotherapy. Of 8 patients, 7 underwent resection of the residual tumor. Surgical or pathological CR was obtained in 5 of these 7 patients, 4 patients of whom were alive with no evidence of disease 29 to 49 months after initial consultation: the other patient died with recurrence 20 months after initial visit. On the other hand, super high-dose chemotherapy with PBSCT was performed for one patient as consolidation, and for 3 patients with recurrence. Of these 4 patients, one died from disease 6 months after detection of recurrence. The other 3 patients were alive with no evidence of disease at 7-37 months after initial visit. The 1- and 3-year disease-free survival rates were 88% and 72%, respectively. In conclusion, super high-dose chemotherapy with PBSCT can be done safely and could be useful for patients with poor-risk germ cell tumor.
URI: http://hdl.handle.net/2433/114152
PubMed ID: 10637747
Appears in Collections:Vol.45 No.11

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.